Overview

Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Status:
Recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

ECOG-ACRIN Cancer Research Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Capecitabine
Carboplatin
Cisplatin
Succinylcholine